Ultrasound genetic modulation of cells expressing bacterial mechanosensitive proteins
Patent Information
- Application Number
- JP2023527259
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-04
- Filing Date
- 2021-11-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000059_0000 
Figure 00000059_0001 
Figure 00000060_0000
Abstract
Claims
1. 1. A method for inducing cation influx in a cell, comprising the steps of: expressing in said cell a polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like3, MscSfam, or MscS-like, wherein said polypeptide is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively; and applying ultrasound to the cells, thereby inducing cation influx in the cells.
2. The method of claim 1 , wherein the cells are sensitized to mechanical deformation or stretching caused by ultrasound.
3. 1. A method for making cells responsive or sensitizing to mechanical deformation or stretch caused by ultrasound, comprising the steps of: (a) transducing a cell to express a heterologous bacterial mechanosensory polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like3, MscSfam, or MscS-like, wherein said mechanosensory polypeptide is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively; (b) applying ultrasound to the cells; and (c) inducing cation influx and changes in cellular activity and / or function in cells expressing the bacterial mechanosensory polypeptide following application of ultrasound, thereby rendering the cells responsive or sensitized to mechanical deformation or stretch caused by ultrasound.
4. The method of any one of claims 1 to 3, wherein the polynucleotide sequence encoding the bacterial mechanosensory polypeptide is codon-optimized for expression in mammalian or human cells and is non-naturally occurring.
5. The method according to any one of claims 1 to 4, wherein the heterologous bacterial mechanosensory polypeptide is expressed in the cell following transduction of the cell with a plasmid or viral vector comprising a polynucleotide sequence encoding the polypeptide.
6. 6. The method of claim 5, wherein the cell is a mammalian cell or a human cell and / or is transduced by a viral vector selected from a lentiviral vector or an adeno-associated viral (AAV) vector.
7. The method of any one of claims 1 to 6, wherein the cell is one or more of a muscle cell, a cardiomyocyte, an insulin-secreting cell, a glial cell, or a neuronal cell.
8. The neuronal cells are selected from the group consisting of motor neurons, sensory neurons, interneurons, and agouti-related protein-expressing positive (AGRP- +ve 8. The method of claim 7, wherein the neuron is selected from the group consisting of:
9. the ultrasound has a frequency of about 0.2 MHz to about 20 MHz; and / or The method of any one of claims 1 to 8, wherein the ultrasound has a focal zone of about 1 cubic millimeter to about 1 cubic centimeter.
10. 1. A pharmaceutical composition for use in a method of treating a disease or disorder in a subject in need thereof, comprising: the cell expressing a heterologous nucleic acid molecule encoding a mechanosensory polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like3, MscSfam, or MscS-like, wherein said mechanosensory polypeptide is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively; The method includes applying ultrasound to the cells to treat the disease or disorder in the subject. The pharmaceutical composition.
11. 1. A pharmaceutical composition for use in a method of treating a disease or disorder in a mammalian subject in need thereof, comprising: the cell transduced with a polynucleotide molecule encoding a heterologous bacterial mechanosensory polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like3, MscSfam, or MscS-like, wherein said mechanosensory polypeptide is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively; The method comprises the steps of applying ultrasound to cells expressing the bacterial mechanosensory polypeptide; inducing cation influx and altered cellular activity and / or function in cells expressing said bacterial mechanosensory polypeptide following application of said ultrasound, thereby treating said disease or disorder in said subject. The pharmaceutical composition.
12. 12. The pharmaceutical composition of claim 10 or 11, wherein the cell is one or more of a muscle cell, a cardiomyocyte, an insulin-secreting cell, a glial cell, or a neuronal cell.
13. The cells are selected from the group consisting of motor neurons, sensory neurons, interneurons, and agouti-related protein expression positive (AGRP- +ve 13. The pharmaceutical composition of claim 12, wherein the neuronal cell is selected from the group consisting of:
14. The pharmaceutical composition of any one of claims 10 to 13, wherein the ultrasound is applied to the cells in the hypothalamus of the subject.
15. The pharmaceutical composition according to any one of claims 10 to 14, wherein the disease or disorder is a neurological disease or disorder, or a neural circuit disease, selected from Parkinson's disease, depression, muscle weakness, muscle atrophy, muscle degeneration obsessive-compulsive disorder, eating disorder, chronic pain, epilepsy, spinal cord injury, anxiety, Alzheimer's disease, post-traumatic stress disorder (PTSD), or cervical spinal cord injury.
16. 1. A pharmaceutical composition for use in a method of remotely modulating neuronal activity in a subject in need thereof, comprising: the neuronal cell expressing a heterologous nucleic acid molecule encoding a mechanosensory polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like3, MscSfam, or MscS-like, wherein said mechanosensory polypeptide is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively; The method includes applying ultrasound to neurons at a first location in the subject's nervous system and modulating activity of neurons at a second location in the subject's nervous system, the second location being distal to the first location. The pharmaceutical composition.
17. The neural cells are selected from brain neuronal cells, hippocampal neuronal cells, or motor neurons; and / or 17. The pharmaceutical composition of claim 16, wherein the first site is the spinal cord and the second site is muscle tissue downstream of the first site.
18. The pharmaceutical composition of claim 16 or 17, wherein the polynucleotide sequence encoding the bacterial mechanosensory polypeptide is codon-optimized for expression in mammalian or human cells and is non-naturally occurring.
19. The pharmaceutical composition according to any one of claims 16 to 18, wherein the cells are transduced by a viral vector selected from a lentiviral vector or an adenovirus-associated viral (AAV) vector.
20. the ultrasound has a frequency of about 0.2 MHz to about 20 MHz; and / or the ultrasound has a focal zone of about 1 cubic millimeter to about 1 cubic centimeter; and / or The ultrasound is generated using a photoacoustic system, a transducer, or a lead zirconate titanate (PZT) transducer; and / or application of the ultrasound to the cells results in a behavioral change in the subject. A pharmaceutical composition according to any one of claims 16 to 19.
21. A plasmid or viral vector comprising a polynucleotide encoding a polypeptide selected from MscL, G22S, MscS, MscK, MscMJLR, MscMJ, MscS-like 3, MscSfam, or MscS-like, The polynucleotide is codon-optimized for expression in a mammalian cell and is encoded by a polynucleotide sequence having at least 85%, at least 90%, at least 95%, or at least 98% sequence identity to a polynucleotide sequence selected from SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:3, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:23, or SEQ ID NO:26, respectively.
22. 22. The plasmid or vector of claim 21 , wherein the vector is a lentiviral vector or an adeno-associated viral (AAV) vector.
23. A cell comprising the plasmid or viral vector of claim 21 or 22.
24. one or more of a muscle cell, a cardiomyocyte, an insulin-secreting cell, a glial cell, or a neuronal cell; or Motor neurons, sensory neurons, interneurons, or agouti-related protein expression positive (AGRP- +ve ) neurons, and / or a mammalian cell or a human cell, The cell of claim 23.
